Skip to main content
AmigoFish

Sacituzumab +/- Pembrolizumab FDA Approval in Triple Negative Breast Cancer: ASCENT-03 / ASCENT-04

From Oncology Brothers: Practice-Changing Cancer Discussions · · 20 min

This plays from the publisher's own server. We do not host a copy.

Open at the source

Not rated yet

Description

In this episode of the Oncology Brothers podcast, we dived deep into the recent FDA approvals for sacituzumab govitecan in frontline settings for metastatic triple-negative breast cancer. Joined by Dr. Sara Tolaney, a breast medical oncologist from the Dana-Farber Cancer Institute, we discussed the exciting developments in breast cancer treatment, with ASCENT-03 and ASCENT-04 trials.

Key topics covered in this episode include:

- Overview of the recent FDA approvals for antibody-drug conjugates (ADCs) in breast cancer

- Detailed discussion on the ASCENT-04 trial focusing on PD-L1–positive metastatic triple-negative breast cancer

- Insights into the ASCENT-03 trial for PD-L1–negative disease

- Comparison of sacituzumab govitecan and datopotamab deruxtecan (Dato-DXd), including their efficacy and side effect profiles

- Management strategies for common side effects such as neutropenia and diarrhea

Listen us on:

Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o

Follow us on social media:

- ⁠X/Twitter: https://x.com/oncbrothers

- Instagram: https://www.instagram.com/oncbrothers

- Website: https://oncbrothers.com/

Join us as we explored the evolving landscape of breast cancer treatment and the importance of shared decision-making in patient care. Don't forget to like, subscribe, and hit the notification bell for more updates from the Oncology Brothers!

#TripleNegativeBreastCancer, #Sacituzumab, #ASCENT03, #ASCENT04, #OncologyBrothers

Back to Oncology Brothers: Practice-Changing Cancer Discussions · Report a problem